<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gemtuzumab ozogamicin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gemtuzumab ozogamicin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gemtuzumab ozogamicin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8968" href="/d/html/8968.html" rel="external">see "Gemtuzumab ozogamicin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12508" href="/d/html/12508.html" rel="external">see "Gemtuzumab ozogamicin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F50615333"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with gemtuzumab ozogamicin.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50591725"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mylotarg</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54323150"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mylotarg</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1016499"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F50615427"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Premedicate with oral acetaminophen 15 mg/kg (maximum dose: 650 mg/dose) and oral or IV diphenhydramine 1 mg/kg (maximum dose: 50 mg/dose) 1 hour prior to infusion and oral or IV methylprednisolone 1 mg/kg 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed. Repeat methylprednisolone (or equivalent corticosteroid) dose for any sign of infusion-related reaction (eg, fever, chills, hypotension, dyspnea) during or within 4 hours of the infusion. Dosing presented as mg/<b>kg</b> and mg/m<sup>2</sup>; use precaution. Antiemetics may be recommended to prevent nausea and vomiting; in pediatrics, doses of 3 to 9 mg/m<sup>2</sup> are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count &gt;30,000/mm<sup>3</sup>) is present; in pediatric protocols, conventional chemotherapy is typically administered several days (3 to 7) before gemtuzumab dose to achieve hematologic targets.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6d6a8d5-2e9c-46af-8b90-5e2c47a76b87">Acute myeloid leukemia, CD33-positive, newly diagnosed de novo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, CD33-positive, newly diagnosed de novo</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction:</i>
<b>Note: </b>Use in combination with standard chemotherapy; in AAML0531, gemtuzumab was administered on day 6 and used in combination therapy with cytarabine, daunorubicin, and etoposide; no gemtuzumab administered during second induction cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25092781','lexi-content-ref-28674028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25092781','lexi-content-ref-28674028'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &lt;0.6 m<sup>2</sup>: IV: 0.1 mg/<b>kg</b>/dose once.</p>
<p style="text-indent:-2em;margin-left:8em;">BSA ≥0.6 m<sup>2</sup>: IV: 3 mg/m<sup>2</sup>/dose once.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intensification course 2:</i>
<b>Note:</b> Use in combination with standard chemotherapy; in AAML0531, gemtuzuamb was administered on day 7 and used in combination therapy with cytarabine and mitoxantrone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25092781','lexi-content-ref-28674028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25092781','lexi-content-ref-28674028'])">Ref</a></span>); assess risk versus benefit prior to administration.</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &lt;0.6 m<sup>2</sup>: IV: 0.1 mg/<b>kg</b>/dose once.</p>
<p style="text-indent:-2em;margin-left:8em;">BSA ≥0.6 m<sup>2</sup>: IV: 3 mg/m<sup>2</sup>/dose once.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="492d4e0f-38ab-4f8b-bf11-7b968f672eb9">Acute myeloid leukemia, CD33-positive, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, CD33-positive, refractory/relapse: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer labeling: Children ≥2 years and Adolescents: IV: 3 mg/m<sup>2</sup>/dose, administer as a single course of monotherapy on days 1, 4, and 7; maximum dose: 4.5 mg/dose per the manufacturer and based on adult data; however, pediatric protocols do not cap dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate dosing: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15886328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15886328'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;3 years: IV: 0.2 mg/<b>kg</b>/dose on days 1 and 15.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥3 years and Adolescents: IV: 6 mg/m<sup>2</sup>/dose on days 1 and 15.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Combination therapy</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467731'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Capizzi II regimen: Used in combination with cytarabine and l-asparaginase:</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;3 years: IV: 0.07 mg/<b>kg</b>/dose on day 3.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥3 years and Adolescents: IV: 2 mg/m<sup>2</sup>/dose on day 3.</p>
<p style="text-indent:-2em;margin-left:8em;">MA regimen: Used in combination with mitoxantrone and cytarabine.</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;3 years: IV: 0.1 mg/<b>kg</b>/dose on day 7.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥3 years and Adolescents: IV: 3 mg/m<sup>2</sup>/dose on day 7.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonhematologic toxicity (when administering gemtuzumab ozogamicin either as monotherapy or in combination with chemotherapy): </b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Infusion-related reactions</i>: See "Administration: Pediatric."</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe bleeding or hemorrhage: </i>May require treatment delay or permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Other severe or life-threatening toxicities: </i>Delay gemtuzumab ozogamicin treatment until recovery to a severity of no more than mild; omit scheduled dose if delayed more than 2 days between sequential infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hematologic toxicity (when administering gemtuzumab ozogamicin in combination with chemotherapy):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Persistent thrombocytopenia:</i> Prior to each cycle, delay therapy until platelet count ≥75,000/mm<sup>3</sup>; if platelet count does not recover to ≥75,000/mm<sup>3</sup>, discontinue gemtuzumab in subsequent induction or intensification cycles.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Persistent neutropenia:</i> Prior to each cycle, delay therapy until neutrophil count ≥1,000/mm<sup>3</sup>; if neutrophil count does not recover to ≥1,000/mm<sup>3</sup>, discontinue gemtuzumab in subsequent induction or intensification cycles.</p></div>
<div class="block dorp drugH1Div" id="F51112394"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, data has shown that creatinine clearance in this range has no clinically significant effect on the pharmacokinetic profile.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51112395"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment had no clinically significant effects on the pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN) and severe (total bilirubin &gt;3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment</i>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For total bilirubin &gt;2 times ULN or AST and/or ALT &gt;2.5 times ULN: Delay gemtuzumab ozogamicin until recovery of total bilirubin to ≤2 times ULN and AST and ALT to ≤2.5 times ULN prior to each dose. Omit scheduled dose if delayed more than 2 days between sequential infusions.</p>
<p style="text-indent:-2em;margin-left:6em;">Veno-occlusive disease (VOD): Discontinue gemtuzumab ozogamicin.</p></div>
<div class="block doa drugH1Div" id="F175882"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8968" href="/d/html/8968.html" rel="external">see "Gemtuzumab ozogamicin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV 1 hour prior to gemtuzumab ozogamicin infusion, and methylprednisolone 1 mg/kg (or equivalent) orally or IV within 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed. Repeat methylprednisolone (or equivalent) dose for any sign of infusion-related reaction (eg, fever, chills, hypotension, dyspnea) during or within 4 hours of the infusion. Institute appropriate measures to prevent tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count &gt;30,000/mm<sup>3</sup>) is present.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6d6a8d5-2e9c-46af-8b90-5e2c47a76b87">Acute myeloid leukemia, CD33-positive, newly diagnosed de novo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, CD33-positive, newly diagnosed de novo: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Combination therapy: </i>Note:</b> A treatment course consists of 1 induction cycle and 2 consolidation cycles (in combination with chemotherapy).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction: </i>3 mg/m<sup>2</sup> (maximum: 4.5 mg/dose) on days 1, 4, and 7 (in combination with daunorubicin and cytarabine). If a second induction cycle is required, do NOT administer gemtuzumab ozogamicin during that second induction cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation (2 cycles):</i> 3 mg/m<sup>2</sup> (maximum: 4.5 mg/dose) on day 1 (in combination with daunorubicin and cytarabine).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Single-agent regimen: </i>Note:</b> A treatment course consists of 1 induction cycle and up to 8 cycles of continuation therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction: </i>6 mg/m<sup>2</sup> on day 1 (no maximum dose) followed by 3 mg/m<sup>2</sup> (no maximum dose) on day 8 (as monotherapy).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuation:</i> 2 mg/m<sup>2</sup> (no maximum dose) on day 1 every 4 weeks (as monotherapy) for up to 8 continuation cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Off-label dose:</b> Favorable cytogenetics: </i>Adults &lt;60 years of age: 3 mg/m<sup>2</sup> on day 1 of course 1 (in combination with induction chemotherapy) and on day 1 of course 3 (in combination with chemotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172891'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="492d4e0f-38ab-4f8b-bf11-7b968f672eb9">Acute myeloid leukemia, CD33-positive, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, CD33-positive, relapsed/refractory:</b>
<b>IV:</b> 3 mg/m<sup>2</sup> (maximum: 4.5 mg/dose) on days 1, 4, and 7 (as monotherapy); treatment consists of a single course of therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f133373-607c-467b-8bff-de6df2e90e5c">Acute promyelocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia (off-label use): IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Single-agent therapy (relapsed disease):</b></i> 6 mg/m<sup>2</sup> on days 1 and 15; for patients testing PCR negative after 2 doses, a third dose was administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15187030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15187030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Combination therapy (high-risk patients with newly diagnosed disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19075265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19075265'])">Ref</a></span>):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction:</i> 9 mg/m<sup>2</sup> as a single dose on day 1 (in combination with arsenic trioxide and tretinoin).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Post remission therapy (if arsenic trioxide or tretinoin discontinued due to toxicity):</i> 9 mg/m<sup>2</sup> once every 4 to 5 weeks until 28 weeks after complete remission.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990904"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl 30 to 89 mL/minute had no clinically significant effects on the pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988166"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment had no clinically significant effects on the pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN) and severe (total bilirubin &gt;3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b> Total bilirubin &gt;2 times ULN or AST and/or ALT &gt;2.5 times ULN: Delay gemtuzumab ozogamicin until recovery of total bilirubin to ≤2 times ULN and AST and ALT to ≤2.5 times ULN prior to each dose. Omit scheduled dose if delayed more than 2 days between sequential infusions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Veno-occlusive disease (VOD):</b> Discontinue gemtuzumab ozogamicin.</p></div>
<div class="block adr drugH1Div" id="F175852"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiotoxicity (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Endocrine disease (metabolic: 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (21%), nausea and vomiting (21%), stomatitis (21%; grade 3: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (18%; grades ≥3: 18%), hemorrhage (23% to 25%; grades ≥3: 7% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (51%), increased serum alanine aminotransferase (16%), increased serum aspartate aminotransferase (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (42% to 44%), sepsis (grade 3: 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (46%), headache (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (79%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (grade 3: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (grade 3: 7%), pulmonary edema (grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic sinusoidal obstruction syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Severe infusion related reactions</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Neutropenic enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemorrhagic cystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pneumonia due to <i>Pneumocystis jirovecii</i>, pulmonary infection (fungal infection and bacterial infection, including <i>Stenotrophomonas</i>)</p></div>
<div class="block coi drugH1Div" id="F175866"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gemtuzumab ozogamicin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F175849"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Gemtuzumab ozogamicin is myelosuppressive, and prolonged thrombocytopenia (&gt;42 days post dose) has been reported. Monitor blood counts prior to each dose (and frequently after therapy completion) until resolution of cytopenias. Provide supportive care per standard practice as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Life-threatening or fatal hemorrhage due to prolonged thrombocytopenia may occur with gemtuzumab ozogamicin therapy. Over 90% of patients in a clinical study experienced thrombocytopenia, with 20% experiencing grade 3 or 4 toxicity. Fatal bleeding events included cerebral, intracranial, and subdural hematomas. Monitor platelet counts prior to each dose and until resolution of cytopenias; monitor for signs/symptoms of bleeding and provide supportive care as clinically indicated. In addition to supportive care, severe bleeding, hemorrhage, or persistent thrombocytopenia may require treatment delay or permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: <b>[US Boxed Warning]: Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with gemtuzumab ozogamicin.</b> In a study in adults, the median time to VOD onset was 9 days (range: 2 to 298 days); some events occurred within 28 days of any dose, and 1 case occurred more than 28 days after the last dose. The risk for VOD may be higher in adults who receive higher gemtuzumab ozogamicin doses (as monotherapy), in patients with moderate to severe baseline hepatic impairment, in patients receiving gemtuzumab ozogamicin after hematopoietic stem cell transplant (HSCT), and in patients who receive HSCT after treatment with gemtuzumab ozogamicin. Although no relationship was found between the incidence of VOD and the time of HSCT relative to higher gemtuzumab ozogamicin doses, one clinical study recommended an interval of 2 months between the last gemtuzumab ozogamicin dose and transplant. In pediatric patients, VOD was observed with higher doses of gemtuzumab (Parigger 2016) and in patients undergoing HSCT, VOD presented within 30 days post-HSCT in most cases, which is similar to observations in adult patients; a decreased risk of VOD was observed with an interval &gt;3 months between last gemtuzumab dose and transplant (Arceci 2005; Wadleigh 2003). Signs/symptoms of VOD include rapid weight gain, ascites, hepatomegaly (may be painful), and bilirubin/transaminase elevations. Monitor ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose; more frequent monitoring of liver function tests and clinical symptoms is recommended in patients who develop abnormal liver function tests during therapy. Patients proceeding to HSCT after gemtuzumab ozogamicin therapy should also be monitored closely and frequently for liver function abnormalities. Hepatotoxicity may require dose interruption or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/infusion reaction: Severe hypersensitivity reactions (including anaphylaxis) and other infusion-related reactions may occur within 24 hours of infusion; may be life-threatening or fatal. Infusion-related symptoms may include fever, chills, hypotension, tachycardia, hypoxia, and/or respiratory failure. Premedicate prior to each gemtuzumab ozogamicin dose with acetaminophen, diphenhydramine, and methylprednisolone; monitor vital signs frequently throughout infusion. Immediately interrupt infusion if infusion-related reactions develop (particularly dyspnea, bronchospasm, or hypotension). Monitor during and for at least 1 hour post-infusion or until signs/symptoms resolve completely. Discontinue permanently for anaphylaxis, including severe respiratory symptoms or clinically significant hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT interval prolongation: Prolongation of the QT interval has been reported in patients treated with other calicheamicin-containing medications. Obtain ECGs and monitor electrolytes prior to therapy initiation and as clinically needed when administering gemtuzumab ozogamicin to patients with a history of (or predisposition for) QTc prolongation, who are taking medications known to prolong the QT interval, and in those with electrolyte disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (including renal failure) may occur as a consequence of leukemia treatment, adequate hydration and prophylactic antihyperuricemic medication must be instituted prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute myeloid leukemia with high-risk cytogenetics: In a subgroup analysis, standard combination chemotherapy in combination with gemtuzumab ozogamicin did not improve event-free survival in patients with high-risk cytogenetics. Consider risk versus benefit of continuing treatment with gemtuzumab ozogamicin in combination with chemotherapy in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperleukocytosis: Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count ≥30,000/mm<sup>3</sup>) is present.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: When gemtuzumab ozogamicin was used as a single agent, patients ≥65 years of age with relapsed or refractory acute myeloid leukemia experienced a higher rate of fever and severe infections.</p></div>
<div class="block foc drugH1Div" id="F50591726"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mylotarg: 4.5 mg (1 ea) [contains dextran 40]</p></div>
<div class="block geq drugH1Div" id="F175845"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50643692"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Mylotarg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg (per each): $11,700.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54323151"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mylotarg: 4.5 mg (1 ea) [contains dextran 40]</p></div>
<div class="block accres drugH1Div" id="F11238299"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">In Canada, gemtuzumab is available through a special access program (access information is available from Health Canada).</p></div>
<div class="block admp drugH1Div" id="F52612914"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Antiemetics may be recommended to prevent nausea and vomiting; in pediatrics, doses of 3 to 9 mg/m<sup>2</sup> are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>). Stable for 6 hours at room temperature; if refrigerated, consider time for room temperature equilibration and the infusion duration. Premedicate with oral acetaminophen (15 mg/kg; maximum dose: 650 mg/dose) and oral or IV diphenhydramine (1 mg/kg; maximum dose: 50 mg/dose) administered 1 hour prior to infusion and oral or IV methylprednisolone (1 mg/kg) administered 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: After premedication, infuse over 2 hours through a 0.2-micron polyethersulfone (PES) in-line filter and infusion set made of PVC with DEHP, PVC non-DEHP, polyethylene, or polyurethane. Protect IV infusion container (eg, bag, syringe) from light during infusion using a light-blocking cover (infusion line does not need to be protected from light). Do not administer as IV push or bolus. Monitor for infusion reactions during and for at least 1 hour after the end of infusion. Do not mix or administer with other medications.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Infusion-related reactions:</i> Interrupt the infusion and initiate appropriate medical and supportive care management; administer acetaminophen, diphenhydramine, and/or methylprednisolone, if needed. Upon symptom resolution, consider resuming the infusion at no more than half the rate at which the reaction occurred; repeat infusion interruption in the event of symptom recurrence. Permanently discontinue gemtuzumab ozogamicin for severe or life-threatening infusion reactions.</p></div>
<div class="block adm drugH1Div" id="F175863"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 2 hours through a 0.2-micron polyethersulfone in-line filter and infusion set made of PVC with DEHP, PVC non-DEHP, polyethylene, or polyurethane. Protect IV bag from light during infusion using a light-blocking cover (infusion line does not need to be protected from light). Do not administer as IV push or bolus.</p>
<p style="text-indent:-2em;margin-left:2em;">Premedicate with acetaminophen, diphenhydramine, and methylprednisolone prior to each infusion (see Dosing). Monitor for infusion reactions during and for at least 1 hour after the end of infusion. If infusion reaction occurs, interrupt infusion and initiate appropriate management. Upon symptom resolution, consider resuming the infusion at no more than half the rate at which the reaction occurred; repeat in the event of symptom recurrence (discontinue for severe or life-threatening infusion reaction).</p>
<p style="text-indent:-2em;margin-left:2em;">Do not mix or administer with other medications.</p></div>
<div class="block hazard drugH1Div" id="F49132602"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F175871"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). Store in original carton to protect from light. Do not freeze. Reconstituted solutions should be used immediately or may be refrigerated for up to 16 hours or at room temperature (up to 30°C [86°F]) for up to 3 hours; do not freeze. Reconstituted solutions and diluted solutions should be protected from light. If not used immediately, solutions diluted for infusion are stable at room temperature (up to 30°C [86°F]) for up to 6 hours or for up to 18 hours when refrigerated, which includes the 2-hour infusion time and the time needed for preparation.</p></div>
<div class="block usep drugH1Div" id="F53567089"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) (FDA approved in ages ≥1 month and adults); treatment of relapsed or refractory CD33-positive AML (FDA approved in ages ≥2 years and adults).</p></div>
<div class="block mst drugH1Div" id="F3401641"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gemtuzumab ozogamicin may be confused with gemcitabine, inotuzumab ozogamicin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299395"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F175854"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306873"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the last gemtuzumab ozogamicin dose. Males with female partners of reproductive potential should use effective contraception during therapy and for at least 3 months after the last gemtuzumab ozogamicin dose.</p></div>
<div class="block pri drugH1Div" id="F175867"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data animal reproduction studies, in utero exposure to gemtuzumab ozogamicin may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53567090"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to each dose, and more frequently if clinically indicated, particularly if sinusoidal obstruction syndrome (veno-occlusive disease) is suspected and/or in HSCT patients; blood counts frequently (before each dose and at least 3 times per week through recovery from treatment-related toxicities); serum chemistries at least 3 times per week through recovery from treatment-related toxicities; electrolytes. Verify pregnancy status in women of reproductive potential prior to therapy initiation. Obtain ECG prior to therapy initiation and as clinically needed when administering to patients with a history of (or predisposition for) QTc prolongation, who are taking medications known to prolong the QT interval, and in those with electrolyte disturbances.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor during and for at least 1 hour after the end of infusion for infusion-related reactions. Monitor for signs and symptoms of sinusoidal obstruction syndrome (rapid weight gain, hepatomegaly, ascites), signs/symptoms of bleeding or hemorrhage, and tumor lysis syndrome.</p></div>
<div class="block pha drugH1Div" id="F175848"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gemtuzumab ozogamicin is a humanized CD-33 directed monoclonal antibody-drug conjugate, which is composed of the IgG4 kappa antibody gemtuzumab linked to a cytotoxic calicheamicin derivative. CD33 is expressed on leukemic cells in over 80% of patients with AML (Castaigne 2012). Gemtuzumab ozogamicin binds to the CD33 antigen, resulting in internalization of the antibody-antigen complex. Following internalization, the calicheamicin derivative is released inside the myeloid cell. The calicheamicin derivative binds to DNA resulting in double strand breaks, inducing cell cycle arrest and apoptosis.</p></div>
<div class="block phk drugH1Div" id="F175865"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Antibody portion: ~21.4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Calicheamicin: ~97% to human plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Calicheamicin is extensively metabolized, primarily through nonenzymatic reduction of the disulfide moiety</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Based on a 9 mg/m<sup>2</sup> dose: Antibody portion: 62 hours (after first dose); 90 hours (after second dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Based on a 9 mg/m<sup>2</sup> dose: Antibody portion: 0.35 L/hour (after first dose); 0.15 L/hour (after second dose)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175868"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mylotac | Mylotarg</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mylotarg</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Maylotarg</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26811524">
<a name="26811524"></a>Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. <i>J Clin Oncol</i>. 2016;34(9):972-979.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/26811524/pubmed" id="26811524" target="_blank">26811524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467731">
<a name="18467731"></a>Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>J Clin Oncol. </i>2008;26(14):2390-3295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/18467731/pubmed" id="18467731" target="_blank">18467731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15886328">
<a name="15886328"></a>Arceci RJ, Sande J, Lange B, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Pediatric Patients With Advanced CD33+ Acute Myeloid Leukemia. <i>Blood.</i> 2005;106(4):1183-1188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/15886328/pubmed" id="15886328" target="_blank">15886328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286091">
<a name="15286091"></a>Buckwalter M, Dowell JA, Korth-Bradley J, et al. Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. <i>J Clin Pharmacol. </i>2004;44(8):873-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/15286091/pubmed" id="15286091" target="_blank">15286091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172891">
<a name="21172891"></a>Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. <i>J Clin Oncol</i>, 2011;29(4):369-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/21172891/pubmed" id="21172891" target="_blank">21172891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22482940">
<a name="22482940"></a>Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet</i>. 2012;379(9825):1508-1516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/22482940/pubmed" id="22482940" target="_blank">22482940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castaigne.2014">
<a name="Castaigne.2014"></a>Castaigne S, Pautas C, Terre C, et al. Final analysis of the ALFA 0701 Study. <i>Blood</i>. 2014;124(21):376.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21766293">
<a name="21766293"></a>Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/21766293/pubmed" id="21766293" target="_blank">21766293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092781">
<a name="25092781"></a>Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/25092781/pubmed" id="25092781" target="_blank">25092781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21902686">
<a name="21902686"></a>Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/21902686/pubmed" id="21902686" target="_blank">21902686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28674028">
<a name="28674028"></a>Guest EM, Aplenc R, Sung L, et al. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. <i>Blood</i>. 2017;130(7):943-945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/28674028/pubmed" id="28674028" target="_blank">28674028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16116598">
<a name="16116598"></a>Larson RA, Sievers EL, Stadtmauer EA, et al, "Final Report of the Efficacy and Safety of Gemtuzumab Ozogamicin (Mylotarg) in Patients With CD33-Positive Acute Myeloid Leukemia in First Recurrence," <i>Cancer</i>, 2005, 104(7):1442-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/16116598/pubmed" id="16116598" target="_blank">16116598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15187030">
<a name="15187030"></a>Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood.</i> 2004;104(7):1995-1999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/15187030/pubmed" id="15187030" target="_blank">15187030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylotarg.1">
<a name="Mylotarg.1"></a>Mylotarg (gemtuzumab ozogamicin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26646091">
<a name="26646091"></a>Parigger J, Zwaan CM, Reinhardt D, Kaspers GJ. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. <i>Expert Rev Anticancer Ther</i>. 2016;16(2):137-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/26646091/pubmed" id="26646091" target="_blank">26646091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19075265">
<a name="19075265"></a>Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. <i>J Clin Oncol.</i> 2009;27(4):504-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/19075265/pubmed" id="19075265" target="_blank">19075265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18812465">
<a name="18812465"></a>Sanz MA, Grimwade D, Tallman MS, et al, “Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,” <i>Blood</i>, 2009, 113(9):1875-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/18812465/pubmed" id="18812465" target="_blank">18812465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12738663">
<a name="12738663"></a>Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i>. 2003;102(5):1578-1582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/12738663/pubmed" id="12738663" target="_blank">12738663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12543868">
<a name="12543868"></a>Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab Ozogamicin: First Clinical Experiences in Children With Relapsed/Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis. <i>Blood</i>. 2003; 101(10):3868-3871.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/12543868/pubmed" id="12543868" target="_blank">12543868</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13174 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
